NCT06809114View on ClinicalTrials.gov

FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

August 31, 2028

Conditions
Solid Tumor
Interventions
DRUG

AT03-65

Treatment will continue until disease progression, unacceptable toxicity, subject withdrawal of consent or death.

Sponsors
All Listed Sponsors
lead

Axcynsis Therapeutics Pte Ltd

INDUSTRY